NCT01081886

Brief Summary

The objective of this clinical study is to evaluate the operative performance of the PEAK PlasmaBlade 4.0 during total knee replacement; to monitor and record post-operative pain, activity level, narcotic consumption, adverse events, and skin scarring following surgery; and compare these outcomes to the current standard of care (SOC).

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
24

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jun 2010

Geographic Reach
1 country

2 active sites

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 4, 2010

Completed
1 day until next milestone

First Posted

Study publicly available on registry

March 5, 2010

Completed
3 months until next milestone

Study Start

First participant enrolled

June 1, 2010

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2011

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2011

Completed
1.3 years until next milestone

Results Posted

Study results publicly available

January 3, 2013

Completed
Last Updated

January 8, 2013

Status Verified

January 1, 2013

Enrollment Period

1.3 years

First QC Date

March 4, 2010

Results QC Date

November 29, 2012

Last Update Submit

January 3, 2013

Conditions

Keywords

Total knee arthroplastyPlasmaBladeElectrosurgeryPEAK SurgicalMedtronic Advanced EnergyMedtronic

Outcome Measures

Primary Outcomes (1)

  • Post-operative Pain

    Wong-Baker FACES Visual Analog Scale, 0 (no hurt) to 10 (hurts worst). The results represent the mean of each subject's mean pain scores over 10 days.

    Postoperative (0 to 10 days)

Secondary Outcomes (1)

  • Operative Metrics: Operative Time, Estimated Blood Loss, Skin Scarring, Knee Society Score (KSS)

    Intraoperatively and 1-2 weeks postoperatively

Study Arms (2)

PlasmaBlade

EXPERIMENTAL

The PEAK PlasmaBlade will be used for the entirety of the total knee replacement, including the skin incision.

Device: PEAK PlasmaBlade 4.0

Standard of Care

ACTIVE COMPARATOR

Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.

Device: Traditional Electrosurgery with scalpel

Interventions

The PEAK PlasmaBlade will be used for the entirety of the total knee replacement, including the skin incision.

Also known as: Intervention, PlasmaBlade
PlasmaBlade

Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.

Also known as: Scalpel and electrosurgery, SOC
Standard of Care

Eligibility Criteria

Age21 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age between 21 and 80 years old
  • Physically healthy, stable weight
  • Requiring unilateral total knee arthroplasty (TKA)
  • Subject exhibits preoperative radiographic evidence of joint degeneration consistent with TKA that cannot be treated in non-operative fashion
  • Subject has severe knee pain and disability due to degenerative joint disease
  • Subject must understand the nature of the procedure and provide written informed consent prior to the procedure.
  • Subject must be willing and able to comply with all follow-up evaluations
  • Subject must be willing to undergo TKA using the Signature Knee System

You may not qualify if:

  • Age younger than 21 or greater than 80 years old
  • Previous history of infection in the affected joint
  • Peripheral vascular disease
  • Revision procedures
  • BMI \> 35
  • Valgus or varus deformity \> 15 degrees
  • Flexion contracture \> 15 degrees
  • History of diabetes
  • Anticoagulation therapy which cannot be discontinued
  • Cognitive impairment or mental illness
  • Severe cardiopulmonary deficiencies
  • Known coagulopathy
  • Immunocompromised
  • Kidney disease (any type)
  • Unable to follow instructions or complete follow-up
  • +2 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

DeClaire Knee and Orthopedic Institute

Rochester Hills, Michigan, 48307, United States

Location

Texas Health Arlington Memorial Hospital

Arlington, Texas, 76012, United States

Location

MeSH Terms

Conditions

Joint DiseasesOsteoarthritisHyperthermia

Interventions

MethodsElectrosurgery

Condition Hierarchy (Ancestors)

Musculoskeletal DiseasesArthritisRheumatic DiseasesBody Temperature ChangesSigns and SymptomsPathological Conditions, Signs and SymptomsHeat Stress DisordersWounds and Injuries

Intervention Hierarchy (Ancestors)

Investigative TechniquesSurgical Procedures, Operative

Limitations and Caveats

Upon Medtronic's acquisition of PEAK surgical, a study integrity audit was undertaken. Results of the audit showed that patient's rights and safety were maintained, but the source data, including baseline demographics, were unverifiable.

Results Point of Contact

Title
Robert Swain, PhD
Organization
Medtronic Surgical Technologies

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
LTE60
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 4, 2010

First Posted

March 5, 2010

Study Start

June 1, 2010

Primary Completion

September 1, 2011

Study Completion

September 1, 2011

Last Updated

January 8, 2013

Results First Posted

January 3, 2013

Record last verified: 2013-01

Locations